ERX1000 vs metreleptin

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Obesity

Shared mechanism: Leptin · full Obesity pipeline

ERX1000

Developed by ERX Pharmaceuticals

Phase 2 in Obesitysmall molecule
Weak signal

NCT04890873 · Phase 1 · completed

Participants were randomized to ERX1000 or a matching placebo with blinding of both participants and investigators, but the primary endpoints reported are safety measures (adverse events, laboratory, ECG, vital-sign, and exam abnormalities) rather than weight or metabolic efficacy, and no results have been posted. Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Next expected readout: May 2027 · NCT07570758 (registry estimate)

No aligned efficacy figure on record for this race.

metreleptin · Myalept

Marketed by Chiesi Farmaceutici

Phase 2 in Obesityprotein
Partial signal

NCT01155180 · Phase 2 · completed

The trial was randomized, double-blind, and placebo-controlled, but it included only 24 participants (18 leptin and 6 placebo), making it small for a controlled comparison. Its clinical primary endpoint was not accompanied by a reported p-value or confidence interval, so whether the treatment comparison was statistically significant is unclear.

No aligned efficacy figure on record for this race.

Results for Obesity

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointERX1000metreleptin
Body weight, % change—Not reported-6.4% vs -2.0%−4.4 vs placebo360 mcg + 1.25 mg · wk 28 · n 45NCT00673387
25 other results
  • -7.0% vs -2.0% 360 mcg + 2.5 mg · wk 28 · n 45 · Phase 2 · primary NCT00673387
  • -7.0% vs -2.0% 360 mcg + 5.0 mg · wk 28 · n 38 · Phase 2 · primary NCT00673387
  • -6.8% vs -2.0% 180 mcg + 2.5 mg · wk 28 · n 47 · Phase 2 · primary NCT00673387
  • -6.6% vs -2.0% 180 mcg + 5.0 mg · wk 28 · n 46 · Phase 2 · primary NCT00673387
  • -5.8% vs -2.0% 5.0 mg · wk 28 · n 41 · Phase 2 · primary NCT00673387
  • -3.6% vs -3.9% wk 20 · n 19 · Phase 2 · secondary NCT00392925
  • -8.2% vs -3.9% wk 20 · n 36 · Phase 2 · secondary NCT00392925
  • -8.2% vs -8.4% wk 20 · n 19 · Phase 2 · secondary NCT00392925
  • -12.7% vs -8.4% wk 20 · n 36 · Phase 2 · secondary NCT00392925
  • -3.4% vs -3.9% wk 16 · n 19 · Phase 2 · secondary NCT00392925
  • -7.6% vs -3.9% wk 16 · n 36 · Phase 2 · secondary NCT00392925
  • -8.0% vs -8.4% wk 16 · n 19 · Phase 2 · secondary NCT00392925
  • -12.1% vs -8.4% wk 16 · n 36 · Phase 2 · secondary NCT00392925
  • -3.2% vs -3.4% wk 12 · n 19 · Phase 2 · secondary NCT00392925
  • -6.1% vs -3.4% wk 12 · n 36 · Phase 2 · secondary NCT00392925
  • -7.8% vs -8.0% wk 12 · n 19 · Phase 2 · secondary NCT00392925
  • -10.8% vs -8.0% wk 12 · n 36 · Phase 2 · secondary NCT00392925
  • -2.1% vs -2.7% wk 8 · n 19 · Phase 2 · secondary NCT00392925
  • -4.8% vs -2.7% wk 8 · n 36 · Phase 2 · secondary NCT00392925
  • -6.8% vs -7.3% wk 8 · n 19 · Phase 2 · secondary NCT00392925
  • -9.5% vs -7.3% wk 8 · n 36 · Phase 2 · secondary NCT00392925
  • -0.7% vs -1.6% wk 4 · n 19 · Phase 2 · secondary NCT00392925
  • -2.4% vs -1.6% wk 4 · n 36 · Phase 2 · secondary NCT00392925
  • -5.5% vs -6.2% wk 4 · n 19 · Phase 2 · secondary NCT00392925
  • -7.2% vs -6.2% wk 4 · n 36 · Phase 2 · secondary NCT00392925
Weight loss of 5% or more—Not reported—Not reported
Weight loss of 10% or more—Not reported—Not reported
Waist circumference, change (cm)—Not reported-4.7 vs -2.5−2.2 vs placebo360 mcg + 1.25 mg · wk 28 · n 45NCT00673387
31 other results
  • -5.5 vs -2.5 360 mcg + 2.5 mg · wk 28 · n 45 · Phase 2 · secondary NCT00673387
  • -6.5 vs -2.5 360 mcg + 5.0 mg · wk 28 · n 38 · Phase 2 · secondary NCT00673387
  • -3.3 vs -3.0 360 mcg + 1.25 mg · wk 12 · n 45 · Phase 2 · secondary NCT00673387
  • -4.6 vs -3.0 360 mcg + 2.5 mg · wk 12 · n 45 · Phase 2 · secondary NCT00673387
  • -5.2 vs -3.0 360 mcg + 5.0 mg · wk 12 · n 38 · Phase 2 · secondary NCT00673387
  • -5.5 vs -2.5 180 mcg + 2.5 mg · wk 28 · n 47 · Phase 2 · secondary NCT00673387
  • -5.8 vs -2.5 180 mcg + 5.0 mg · wk 28 · n 45 · Phase 2 · secondary NCT00673387
  • -4.9 vs -3.0 180 mcg + 2.5 mg · wk 12 · n 47 · Phase 2 · secondary NCT00673387
  • -4.3 vs -3.0 180 mcg + 5.0 mg · wk 12 · n 45 · Phase 2 · secondary NCT00673387
  • -3.9 vs -2.5 5.0 mg · wk 28 · n 41 · Phase 2 · secondary NCT00673387
  • -3.4 vs -3.0 5.0 mg · wk 12 · n 41 · Phase 2 · secondary NCT00673387
  • -8.0 vs -9.2 wk 20 · n 19 · Phase 2 · secondary NCT00392925
  • -11.6 vs -9.2 wk 20 · n 36 · Phase 2 · secondary NCT00392925
  • -3.6 vs -4.9 wk 20 · n 19 · Phase 2 · secondary NCT00392925
  • -7.3 vs -4.9 wk 20 · n 36 · Phase 2 · secondary NCT00392925
  • -6.8 vs -9 wk 16 · n 19 · Phase 2 · secondary NCT00392925
  • -10.7 vs -9 wk 16 · n 36 · Phase 2 · secondary NCT00392925
  • -2.4 vs -4.8 wk 16 · n 19 · Phase 2 · secondary NCT00392925
  • -6.3 vs -4.8 wk 16 · n 36 · Phase 2 · secondary NCT00392925
  • -7.1 vs -8.5 wk 12 · n 19 · Phase 2 · secondary NCT00392925
  • -9.9 vs -8.5 wk 12 · n 36 · Phase 2 · secondary NCT00392925
  • -2.6 vs -4.2 wk 12 · n 19 · Phase 2 · secondary NCT00392925
  • -5.5 vs -4.2 wk 12 · n 36 · Phase 2 · secondary NCT00392925
  • -5.7 vs -7.8 wk 8 · n 19 · Phase 2 · secondary NCT00392925
  • -8.8 vs -7.8 wk 8 · n 36 · Phase 2 · secondary NCT00392925
  • -1.3 vs -3.5 wk 8 · n 19 · Phase 2 · secondary NCT00392925
  • -4.4 vs -3.5 wk 8 · n 36 · Phase 2 · secondary NCT00392925
  • -5.5 vs -6.8 wk 4 · n 19 · Phase 2 · secondary NCT00392925
  • -7.3 vs -6.8 wk 4 · n 36 · Phase 2 · secondary NCT00392925
  • -1.1 vs -2.5 wk 4 · n 19 · Phase 2 · secondary NCT00392925
  • -3.0 vs -2.5 wk 4 · n 36 · Phase 2 · secondary NCT00392925

Body weight, % change

ERX1000
—Not reported
metreleptin
-6.4% vs -2.0%−4.4 vs placebo360 mcg + 1.25 mg · wk 28 · n 45NCT00673387
25 other results
  • -7.0% vs -2.0% 360 mcg + 2.5 mg · wk 28 · n 45 · Phase 2 · primary NCT00673387
  • -7.0% vs -2.0% 360 mcg + 5.0 mg · wk 28 · n 38 · Phase 2 · primary NCT00673387
  • -6.8% vs -2.0% 180 mcg + 2.5 mg · wk 28 · n 47 · Phase 2 · primary NCT00673387
  • -6.6% vs -2.0% 180 mcg + 5.0 mg · wk 28 · n 46 · Phase 2 · primary NCT00673387
  • -5.8% vs -2.0% 5.0 mg · wk 28 · n 41 · Phase 2 · primary NCT00673387
  • -3.6% vs -3.9% wk 20 · n 19 · Phase 2 · secondary NCT00392925
  • -8.2% vs -3.9% wk 20 · n 36 · Phase 2 · secondary NCT00392925
  • -8.2% vs -8.4% wk 20 · n 19 · Phase 2 · secondary NCT00392925
  • -12.7% vs -8.4% wk 20 · n 36 · Phase 2 · secondary NCT00392925
  • -3.4% vs -3.9% wk 16 · n 19 · Phase 2 · secondary NCT00392925
  • -7.6% vs -3.9% wk 16 · n 36 · Phase 2 · secondary NCT00392925
  • -8.0% vs -8.4% wk 16 · n 19 · Phase 2 · secondary NCT00392925
  • -12.1% vs -8.4% wk 16 · n 36 · Phase 2 · secondary NCT00392925
  • -3.2% vs -3.4% wk 12 · n 19 · Phase 2 · secondary NCT00392925
  • -6.1% vs -3.4% wk 12 · n 36 · Phase 2 · secondary NCT00392925
  • -7.8% vs -8.0% wk 12 · n 19 · Phase 2 · secondary NCT00392925
  • -10.8% vs -8.0% wk 12 · n 36 · Phase 2 · secondary NCT00392925
  • -2.1% vs -2.7% wk 8 · n 19 · Phase 2 · secondary NCT00392925
  • -4.8% vs -2.7% wk 8 · n 36 · Phase 2 · secondary NCT00392925
  • -6.8% vs -7.3% wk 8 · n 19 · Phase 2 · secondary NCT00392925
  • -9.5% vs -7.3% wk 8 · n 36 · Phase 2 · secondary NCT00392925
  • -0.7% vs -1.6% wk 4 · n 19 · Phase 2 · secondary NCT00392925
  • -2.4% vs -1.6% wk 4 · n 36 · Phase 2 · secondary NCT00392925
  • -5.5% vs -6.2% wk 4 · n 19 · Phase 2 · secondary NCT00392925
  • -7.2% vs -6.2% wk 4 · n 36 · Phase 2 · secondary NCT00392925

Weight loss of 5% or more

ERX1000
—Not reported
metreleptin
—Not reported

Weight loss of 10% or more

ERX1000
—Not reported
metreleptin
—Not reported

Waist circumference, change (cm)

ERX1000
—Not reported
metreleptin
-4.7 vs -2.5−2.2 vs placebo360 mcg + 1.25 mg · wk 28 · n 45NCT00673387
31 other results
  • -5.5 vs -2.5 360 mcg + 2.5 mg · wk 28 · n 45 · Phase 2 · secondary NCT00673387
  • -6.5 vs -2.5 360 mcg + 5.0 mg · wk 28 · n 38 · Phase 2 · secondary NCT00673387
  • -3.3 vs -3.0 360 mcg + 1.25 mg · wk 12 · n 45 · Phase 2 · secondary NCT00673387
  • -4.6 vs -3.0 360 mcg + 2.5 mg · wk 12 · n 45 · Phase 2 · secondary NCT00673387
  • -5.2 vs -3.0 360 mcg + 5.0 mg · wk 12 · n 38 · Phase 2 · secondary NCT00673387
  • -5.5 vs -2.5 180 mcg + 2.5 mg · wk 28 · n 47 · Phase 2 · secondary NCT00673387
  • -5.8 vs -2.5 180 mcg + 5.0 mg · wk 28 · n 45 · Phase 2 · secondary NCT00673387
  • -4.9 vs -3.0 180 mcg + 2.5 mg · wk 12 · n 47 · Phase 2 · secondary NCT00673387
  • -4.3 vs -3.0 180 mcg + 5.0 mg · wk 12 · n 45 · Phase 2 · secondary NCT00673387
  • -3.9 vs -2.5 5.0 mg · wk 28 · n 41 · Phase 2 · secondary NCT00673387
  • -3.4 vs -3.0 5.0 mg · wk 12 · n 41 · Phase 2 · secondary NCT00673387
  • -8.0 vs -9.2 wk 20 · n 19 · Phase 2 · secondary NCT00392925
  • -11.6 vs -9.2 wk 20 · n 36 · Phase 2 · secondary NCT00392925
  • -3.6 vs -4.9 wk 20 · n 19 · Phase 2 · secondary NCT00392925
  • -7.3 vs -4.9 wk 20 · n 36 · Phase 2 · secondary NCT00392925
  • -6.8 vs -9 wk 16 · n 19 · Phase 2 · secondary NCT00392925
  • -10.7 vs -9 wk 16 · n 36 · Phase 2 · secondary NCT00392925
  • -2.4 vs -4.8 wk 16 · n 19 · Phase 2 · secondary NCT00392925
  • -6.3 vs -4.8 wk 16 · n 36 · Phase 2 · secondary NCT00392925
  • -7.1 vs -8.5 wk 12 · n 19 · Phase 2 · secondary NCT00392925
  • -9.9 vs -8.5 wk 12 · n 36 · Phase 2 · secondary NCT00392925
  • -2.6 vs -4.2 wk 12 · n 19 · Phase 2 · secondary NCT00392925
  • -5.5 vs -4.2 wk 12 · n 36 · Phase 2 · secondary NCT00392925
  • -5.7 vs -7.8 wk 8 · n 19 · Phase 2 · secondary NCT00392925
  • -8.8 vs -7.8 wk 8 · n 36 · Phase 2 · secondary NCT00392925
  • -1.3 vs -3.5 wk 8 · n 19 · Phase 2 · secondary NCT00392925
  • -4.4 vs -3.5 wk 8 · n 36 · Phase 2 · secondary NCT00392925
  • -5.5 vs -6.8 wk 4 · n 19 · Phase 2 · secondary NCT00392925
  • -7.3 vs -6.8 wk 4 · n 36 · Phase 2 · secondary NCT00392925
  • -1.1 vs -2.5 wk 4 · n 19 · Phase 2 · secondary NCT00392925
  • -3.0 vs -2.5 wk 4 · n 36 · Phase 2 · secondary NCT00392925
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

ERX1000: no structured comparison results are available for Obesity.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. ERX1000: 0 of 4 rows · metreleptin: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricmetreleptin
Dropout rate
—Pramlintide 360 mcg + Metreleptin 1.25 mga
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
show 18 more results
42.9%Pramlintide 360 mcg + Metreleptin 1.25 mg
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
22.2%Pramlintide 360 mcg + Metreleptin 2.5 mg
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
16.2%Pramlintide 360 mcg + Metreleptin 2.5 mg
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
—Pramlintide 360 mcg + Metreleptin 2.5 mg
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
21.4%Pramlintide 360 mcg + Metreleptin 5.0 mg
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
18.9%Pramlintide 360 mcg + Metreleptin 5.0 mg
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
31%Pramlintide 360 mcg + Metreleptin 5.0 mg
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
—Pramlintide 360 mcg + Metreleptin 5.0 mg
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
43.6%360 mcg + 1.25 mg
NCT00673387 · Phase 2 · registry result, not featured evidence · combination
38.5%360 mcg + 2.5 mg
NCT00673387 · Phase 2 · registry result, not featured evidence · combination
46.7%360 mcg + 5.0 mg
NCT00673387 · Phase 2 · registry result, not featured evidence · combination
34.7%180 mcg + 2.5 mg
NCT00673387 · Phase 2 · registry result, not featured evidence · combination
38.5%180 mcg + 5.0 mg
NCT00673387 · Phase 2 · registry result, not featured evidence · combination
43.1%5.0 mg
NCT00673387 · Phase 2 · registry result, not featured evidence
—Metreleptin
NCT00392925 · Phase 2 · registry result, not featured evidence
—Placebo + Metreleptin
NCT00392925 · Phase 2 · registry result, not featured evidence
—Pramlintide + Metreleptin
NCT00392925 · Phase 2 · registry result, not featured evidence · combination
—Pramlintide Acetate + Metreleptin
NCT00392925 · Phase 2 · registry result, not featured evidence · combination
Discontinued due to AEs
—Pramlintide 360 mcg + Metreleptin 1.25 mga
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
show 18 more results
0%Pramlintide 360 mcg + Metreleptin 1.25 mg
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
2.8%Pramlintide 360 mcg + Metreleptin 2.5 mg
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
0%Pramlintide 360 mcg + Metreleptin 2.5 mg
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
—Pramlintide 360 mcg + Metreleptin 2.5 mg
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
0%Pramlintide 360 mcg + Metreleptin 5.0 mg
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
0%Pramlintide 360 mcg + Metreleptin 5.0 mg
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
0%Pramlintide 360 mcg + Metreleptin 5.0 mg
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
—Pramlintide 360 mcg + Metreleptin 5.0 mg
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
2.6%360 mcg + 1.25 mg
NCT00673387 · Phase 2 · registry result, not featured evidence · combination
6.4%360 mcg + 2.5 mg
NCT00673387 · Phase 2 · registry result, not featured evidence · combination
6.7%360 mcg + 5.0 mg
NCT00673387 · Phase 2 · registry result, not featured evidence · combination
2.7%180 mcg + 2.5 mg
NCT00673387 · Phase 2 · registry result, not featured evidence · combination
7.7%180 mcg + 5.0 mg
NCT00673387 · Phase 2 · registry result, not featured evidence · combination
6.9%5.0 mg
NCT00673387 · Phase 2 · registry result, not featured evidence
—Metreleptin
NCT00392925 · Phase 2 · registry result, not featured evidence
—Placebo + Metreleptin
NCT00392925 · Phase 2 · registry result, not featured evidence
—Pramlintide + Metreleptin
NCT00392925 · Phase 2 · registry result, not featured evidence · combination
—Pramlintide Acetate + Metreleptin
NCT00392925 · Phase 2 · registry result, not featured evidence · combination
Serious AEs
0%Pramlintide 360 mcg + Metreleptin 1.25 mga
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
show 18 more results
0%Pramlintide 360 mcg + Metreleptin 1.25 mg
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
0%Pramlintide 360 mcg + Metreleptin 2.5 mg
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
2.7%Pramlintide 360 mcg + Metreleptin 2.5 mg
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
0%Pramlintide 360 mcg + Metreleptin 2.5 mg
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
0%Pramlintide 360 mcg + Metreleptin 5.0 mg
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
2.7%Pramlintide 360 mcg + Metreleptin 5.0 mg
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
6.9%Pramlintide 360 mcg + Metreleptin 5.0 mg
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
0%Pramlintide 360 mcg + Metreleptin 5.0 mg
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
0%360 mcg + 1.25 mg
NCT00673387 · Phase 2 · registry result, not featured evidence · combination
0%360 mcg + 2.5 mg
NCT00673387 · Phase 2 · registry result, not featured evidence · combination
2.7%360 mcg + 5.0 mg
NCT00673387 · Phase 2 · registry result, not featured evidence · combination
2.7%180 mcg + 2.5 mg
NCT00673387 · Phase 2 · registry result, not featured evidence · combination
0%180 mcg + 5.0 mg
NCT00673387 · Phase 2 · registry result, not featured evidence · combination
0%5.0 mg
NCT00673387 · Phase 2 · registry result, not featured evidence
—Metreleptin
NCT00392925 · Phase 2 · registry result, not featured evidence
3.7%Placebo + Metreleptin
NCT00392925 · Phase 2 · registry result, not featured evidence
3.6%Pramlintide + Metreleptin
NCT00392925 · Phase 2 · registry result, not featured evidence · combination
—Pramlintide Acetate + Metreleptin
NCT00392925 · Phase 2 · registry result, not featured evidence · combination
Most frequent reported AEs
Pramlintide 360 mcg + Metreleptin 1.25 mga
upper respiratory tract infection 23.1% (placebo 9.7%)
diarrhea 15.4% (placebo 3.2%)
injection site hemorrhage 15.4% (placebo 3.2%)
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
show 16 more results
Pramlintide 360 mcg + Metreleptin 1.25 mg
nausea 8.6% (placebo 3.2%)
upper respiratory tract infection 8.6% (placebo 9.7%)
muscle spasms 5.7% (placebo 0%)
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
Pramlintide 360 mcg + Metreleptin 2.5 mg
sinusitis 19.4% (placebo 0%)
upper respiratory tract infection 13.9% (placebo 9.7%)
urinary tract infection 8.3% (placebo 0%)
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
Pramlintide 360 mcg + Metreleptin 2.5 mg
nausea 18.9% (placebo 3.2%)
sinusitis 16.2% (placebo 0%)
upper respiratory tract infection 10.8% (placebo 9.7%)
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
Pramlintide 360 mcg + Metreleptin 2.5 mg
injection site pruritus 21.4% (placebo 0%)
injection site urticaria 21.4% (placebo 0%)
bronchitis 14.3% (placebo 0%)
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
Pramlintide 360 mcg + Metreleptin 5.0 mg
upper respiratory tract infection 25% (placebo 9.7%)
nausea 17.9% (placebo 3.2%)
influenza 10.7% (placebo 3.2%)
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
Pramlintide 360 mcg + Metreleptin 5.0 mg
upper respiratory tract infection 58.3% (placebo 9.7%)
nausea 21.6% (placebo 3.2%)
injection site hemorrhage 10.8% (placebo 3.2%)
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
Pramlintide 360 mcg + Metreleptin 5.0 mg
nausea 37.9% (placebo 3.2%)
nasopharyngitis 17.2% (placebo 12.9%)
gastroenteritis 10.3% (placebo 3.2%)
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
Pramlintide 360 mcg + Metreleptin 5.0 mg
injection site erythema 30.8% (placebo 0%)
gastroenteritis 15.4% (placebo 3.2%)
headache 15.4% (placebo 0%)
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
360 mcg + 1.25 mg
nausea 33.3% (placebo 5.3%)
injection site bruising 14.1% (placebo 14.7%)
injection site pruritus 14.1% (placebo 1.3%)
NCT00673387 · Phase 2 · registry result, not featured evidence · combination
360 mcg + 2.5 mg
nausea 37.2% (placebo 5.3%)
injection site erythema 30.8% (placebo 1.3%)
injection site pruritus 23.1% (placebo 1.3%)
NCT00673387 · Phase 2 · registry result, not featured evidence · combination
360 mcg + 5.0 mg
injection site pruritus 29.3% (placebo 1.3%)
injection site erythema 28% (placebo 1.3%)
nausea 25.3% (placebo 5.3%)
NCT00673387 · Phase 2 · registry result, not featured evidence · combination
180 mcg + 2.5 mg
nausea 36% (placebo 5.3%)
injection site pruritus 25.3% (placebo 1.3%)
injection site erythema 20% (placebo 1.3%)
NCT00673387 · Phase 2 · registry result, not featured evidence · combination
180 mcg + 5.0 mg
injection site pruritus 26.9% (placebo 1.3%)
nausea 26.9% (placebo 5.3%)
injection site erythema 21.8% (placebo 1.3%)
NCT00673387 · Phase 2 · registry result, not featured evidence · combination
5.0 mg
injection site erythema 20.8% (placebo 1.3%)
injection site hemorrhage 18.1% (placebo 4%)
injection site pruritus 18.1% (placebo 1.3%)
NCT00673387 · Phase 2 · registry result, not featured evidence
injection site pruritus 25.9%
nausea 25.9%
injection site erythema 18.5%
NCT00392925 · Phase 2 · registry result, not featured evidence
injection site bruising 19.6%
injection site urticaria 16.1%
injection site erythema 14.3%
NCT00392925 · Phase 2 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

metreleptin

Weight -9.92% (n=20) vs -2.68% (n=21) placebo @ 52wkPramlintide 360 mcg + Metreleptin 1.25 mg
percent change · % of baseline
Extension (open-label)
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
show 2 more results
-9.24% (n=27) vs -2.68% (n=21) placebo @ 52wkPramlintide 360 mcg + Metreleptin 2.5 mg
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
-8.2% (n=19) vs -2.68% (n=21) placebo @ 52wkPramlintide 360 mcg + Metreleptin 5.0 mg
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
Weight -6.72 vs -4.59 placebo kg @ 12wkPramlintide 360 mcg + Metreleptin 1.25 mg
absolute change · kg
Extension (open-label)
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
show 2 more results
-7.31 vs -4.59 placebo kg @ 12wkPramlintide 360 mcg + Metreleptin 2.5 mg
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
-7.06 vs -4.59 placebo kg @ 12wkPramlintide 360 mcg + Metreleptin 5.0 mg
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
Weight -8.63 vs -3.7 placebo kg @ 28wkPramlintide 360 mcg + Metreleptin 1.25 mg
absolute change · kg
Extension (open-label)
Week 28 (Baseline for Extension)
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
show 2 more results
-9.91 vs -3.7 placebo kg @ 28wkPramlintide 360 mcg + Metreleptin 2.5 mg
Week 28 (Baseline for Extension)
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
-9.46 vs -3.7 placebo kg @ 28wkPramlintide 360 mcg + Metreleptin 5.0 mg
Week 28 (Baseline for Extension)
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
Weight -9.74 vs -3.53 placebo kg @ 36wkPramlintide 360 mcg + Metreleptin 1.25 mg
absolute change · kg
Extension (open-label)
Week 36 in Extension Study
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
show 2 more results
-10.69 vs -3.53 placebo kg @ 36wkPramlintide 360 mcg + Metreleptin 2.5 mg
Week 36 in Extension Study
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
-9.21 vs -3.53 placebo kg @ 36wkPramlintide 360 mcg + Metreleptin 5.0 mg
Week 36 in Extension Study
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
Weight -9.38 vs -3.1 placebo kg @ 44wkPramlintide 360 mcg + Metreleptin 1.25 mg
absolute change · kg
Extension (open-label)
Week 44 in Extension Study
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
show 2 more results
-10 vs -3.1 placebo kg @ 44wkPramlintide 360 mcg + Metreleptin 2.5 mg
Week 44 in Extension Study
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
-8.6 vs -3.1 placebo kg @ 44wkPramlintide 360 mcg + Metreleptin 5.0 mg
Week 44 in Extension Study
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
Weight -9.26 vs -2.85 placebo kg @ 52wkPramlintide 360 mcg + Metreleptin 1.25 mg
absolute change · kg
Extension (open-label)
Week 52 in Extension Study
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
show 2 more results
-9.65 vs -2.85 placebo kg @ 52wkPramlintide 360 mcg + Metreleptin 2.5 mg
Week 52 in Extension Study
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
-7.98 vs -2.85 placebo kg @ 52wkPramlintide 360 mcg + Metreleptin 5.0 mg
Week 52 in Extension Study
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
Waist Circumference Change -4.03 vs -4.62 placebo cm @ 12wkPramlintide 360 mcg + Metreleptin 1.25 mg
absolute change · cm
Extension (open-label)
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
show 2 more results
-5.77 vs -4.62 placebo cm @ 12wkPramlintide 360 mcg + Metreleptin 2.5 mg
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
-5.7 vs -4.62 placebo cm @ 12wkPramlintide 360 mcg + Metreleptin 5.0 mg
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
Waist Circumference Change -6.48 vs -3.37 placebo cm @ 28wkPramlintide 360 mcg + Metreleptin 1.25 mg
absolute change · cm
Extension (open-label)
Week 28 (baseline in Extension study)
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
show 2 more results
-7.95 vs -3.37 placebo cm @ 28wkPramlintide 360 mcg + Metreleptin 2.5 mg
Week 28 (baseline in Extension study)
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
-8.36 vs -3.37 placebo cm @ 28wkPramlintide 360 mcg + Metreleptin 5.0 mg
Week 28 (baseline in Extension study)
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
Waist Circumference Change -8.79 vs -3.24 placebo cm @ 36wkPramlintide 360 mcg + Metreleptin 1.25 mg
absolute change · cm
Extension (open-label)
Week 36 Extension study
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
show 2 more results
-9.19 vs -3.24 placebo cm @ 36wkPramlintide 360 mcg + Metreleptin 2.5 mg
Week 36 Extension study
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
-8.16 vs -3.24 placebo cm @ 36wkPramlintide 360 mcg + Metreleptin 5.0 mg
Week 36 Extension study
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
Waist Circumference Change -9.09 vs -3.46 placebo cm @ 44wkPramlintide 360 mcg + Metreleptin 1.25 mg
absolute change · cm
Extension (open-label)
Week 44 Extension study
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
show 2 more results
-9.03 vs -3.46 placebo cm @ 44wkPramlintide 360 mcg + Metreleptin 2.5 mg
Week 44 Extension study
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
-8.76 vs -3.46 placebo cm @ 44wkPramlintide 360 mcg + Metreleptin 5.0 mg
Week 44 Extension study
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
Waist Circumference Change -9.08 vs -3.69 placebo cm @ 52wkPramlintide 360 mcg + Metreleptin 1.25 mg
absolute change · cm
Extension (open-label)
Week 52 Extension study
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
show 2 more results
-9.18 vs -3.69 placebo cm @ 52wkPramlintide 360 mcg + Metreleptin 2.5 mg
Week 52 Extension study
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
-7.41 vs -3.69 placebo cm @ 52wkPramlintide 360 mcg + Metreleptin 5.0 mg
Week 52 Extension study
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
Weight -6.93% (n=20) vs -4.56% (n=21) placebo @ 12wkPramlintide 360 mcg + Metreleptin 1.25 mg
percent change · % of baseline
Extension (open-label)
Week 12 of original study
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
show 2 more results
-7.23% (n=27) vs -4.56% (n=21) placebo @ 12wkPramlintide 360 mcg + Metreleptin 2.5 mg
Week 12 of original study
NCT00819234 · Phase 2 · registry result, not featured evidence · combination
-7.17% (n=19) vs -4.56% (n=21) placebo @ 12wkPramlintide 360 mcg + Metreleptin 5.0 mg
Week 12 of original study
NCT00819234 · Phase 2 · registry result, not featured evidence · combination

+ 23 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ERX1000's landscape · metreleptin's landscape